跳至主要内容
临床试验/NCT02109302
NCT02109302已完成不适用

Identification Des Bases Moléculaires De L'éjaculation Prématurée Primaire

Institut National de la Santé Et de la Recherche Médicale, France6 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2014年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70
试验地点
6
主要终点
Number of subjects with genetic mutations of susceptibility to primary PE

研究概览

简要总结

The main objective of our study is to identify the first genetic etiology of primary Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some patients. To this end, we plan to establish a collection of biological samples and a database of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This will lead to improvements in the biological understanding, the "knowledge" of physicians of the disease, and should improve the patients' quality of life. Not all PE cases have the same physiopathology and treatment efficiency, which depend on the specific mechanism involved in the clinical context. Our work will make it possible to develop new therapeutic approaches suitable for a large proportion of individuals presenting PE. This integrative approach combining researchers, patients and ethics committees will facilitate profound reflection, promoting the creation of suitable structures capable of receiving patients for appropriate consultations. This unique study of PE should also favor industrial partnerships.

详细描述

2.1 Main Objective

  • To identify the molecular basis of primary premature ejaculation (PPE) in humans for the development of new adapted therapy.
  • Check and confirm the genetic hypothesis of PPE to fill the void of genetic knowledge about this syndrome.
  • Improve knowledge of physicians on this disease to increase the comfort of life of patients.

2.2 Secondary Objectives

  • Provide the basis for new therapeutic approaches.
  • Expanded knowledge of the aetiology of PE and allow better management of patients.
  • Develop strategies to prevent the consequences, sometimes severe , of this condition on the intimate, personal, social and professional life of these patients. Because all the PE do not have the same pathophysiology and treatment success depends on its relevance to the specific mechanism of the clinical form concerned.
  • Increase the comfort of life of the patients.
  • Eliminate public prejudice based on misconceptions.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • . Patients (index cases ) Prospective and retrospective cases
  • Man aged over 18 years
  • signing the informed consent
  • Presenting primary PE
  • have an affiliation to a social security system
  • Male or female over 18 years
  • be related to the index case
  • signing the informed consent
  • have an affiliation to a social security system
  • Non Inclusion Criteria:
  • . Patients ( index case ) :
  • Be aged under 18
  • have known genetic variations that predispose or can promote psychological disorders that can lead to PE ( eg: Kallman 's Syndrome , micropenis , testicular dysgenesis , Klinfelter syndrome, Leydig cell hypoplasia )
  • have had psycho- social and psycho- traumatic factors in childhood
  • Inability to receive clear information on the protocol
  • Person deprived of liberty by judicial or administrative decision
  • Major Person subject of legal protection or unable to consent
  • Refusal to be informed of an abnormality detected after genetic testing
  • History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample
  • . Related :
  • Age <18 years
  • Inability to receive clear information about the protocol . Unable to participate in the entire study.
  • No coverage by the social security system
  • Absence of signature of consent or refusal of the related party
  • Person deprived of liberty by judicial or administrative decision
  • Major Person subject of legal protection or unable to consent
  • Refusal to be informed of a genetic abnormality detected
  • History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample

排除标准

  • 未提供

结局指标

主要结局

Number of subjects with genetic mutations of susceptibility to primary PE

时间窗: 4 years

We will perform WES (Whole Exome Sequencing) to identify shared defective genes in 20 patients. In case of genetic uniformity and of a genetically homogeneous recruitment, we hope to highlight such a gene in several individuals. As primary PE are very rare, this group should have defective genes at much higher frequencies than in the control population (NCBI, 1000 genome and housing-genome). This will allow us to identify genetic mutations of susceptibility to primary PE.

次要结局

未报告次要终点

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
申办方类型
Other Gov
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验